Latest News

A couple of months ago we reported that Orexigen would be submitting an application for a marketing authorisation to the European Medicines Agency for Contrave, its obesity medication...

It is a while since we last reported on Contrave, the experimental weight loss medication concocted by Orexigen Therapeutics from two existing medications: bupropion and naltrexone...

We previously reported that Contrave could gain approval from the FDA if Orexigen Therapeutics were able to demonstrate in a clinical trial that the treatment was not related to cardiovascular problems...

A team of researchers at Harvard Medical School claim they have created a pill that has the same effect on the body as exercise does without requiring us to move a muscle...

The Food and Drug Administration in the USA has accepted Vivus’s new drug application for the approval of their obesity drug, Qnexa, which will assist with weight loss in obese patients with a BMI of greater than 30 or patients who are overweight with a BMI of greater than 27 and with other health c...